Risk Stratification by Self-Measured Home Blood Pressure across Categories of Conventional Blood Pressure: A Participant-Level Meta-Analysis
Year: 2014
Type: review
Abstract: BACKGROUND: The Global Burden of Diseases Study 2010 reported that hypertension is worldwide the leading risk factor for cardiovascular disease, causing 9.4 million deaths annually. We examined to what extent self-measurement of home blood pressure (HBP) refines risk stratification across increasing categories of conventional blood pressure (CBP). METHODS AND FINDINGS: This meta-analysis included 5,008 individuals randomly recruited from five populations (56.6% women; mean age, 57.1 y). All were not treated with antihypertensive drugs. In multivariable analyses, hazard ratios (HRs) associated with 10-mm Hg increases in systolic HBP were computed across CBP categories, using the following systolic/diastolic CBP thresholds (in mm Hg): optimal, <120/<80; normal, 120-129/80-84; high-normal, 130-139/85-89; mild hypertension, 140-159/90-99; and severe hypertension, ≥160/≥100. Over 8.3 y, 522 participants died, and 414, 225, and 194 had cardiovascular, cardiac, and cerebrovascular events, respectively. In participants with optimal or normal CBP, HRs for a composite cardiovascular end point associated with a 10-mm Hg higher systolic HBP were 1.28 (1.01-1.62) and 1.22 (1.00-1.49), respectively. At high-normal CBP and in mild hypertension, the HRs were 1.24 (1.03-1.49) and 1.20 (1.06-1.37), respectively, for all cardiovascular events and 1.33 (1.07-1.65) and 1.30 (1.09-1.56), respectively, for stroke. In severe hypertension, the HRs were not significant (p≥0.20). Among people with optimal, normal, and high-normal CBP, 67 (5.0%), 187 (18.4%), and 315 (30.3%), respectively, had masked hypertension (HBP≥130 mm Hg systolic or ≥85 mm Hg diastolic). Compared to true optimal CBP, masked hypertension was associated with a 2.3-fold (1.5-3.5) higher cardiovascular risk. A limitation was few data from low- and middle-income countries. CONCLUSIONS: HBP substantially refines risk stratification at CBP levels assumed to carry no or only mildly increased risk, in particular in the presence of masked hypertension. Randomized trials could help determine the best use of CBP vs. HBP in guiding BP management. Our study identified a novel indication for HBP, which, in view of its low cost and the increased availability of electronic communication, might be globally applicable, even in remote areas or in low-resource settings.
Source: PLoS Medicine
Authors: Kei Asayama, Lutgarde Thijs, Jana Brguljan-Hitij, Teemu J. Niiranen, Atsushi Hozawa, José Boggia, Lucas S. Aparicio, Azusa Hara, Jouni K. Johansson, Takayoshi Ohkubo, Christophe Tzourio, George S. Stergiou, Edgardo Sandoya, Ichiro Tsuji, Antti M. Jula, Yutaka Imai, Jan A. Staessen, for the International Database of Home Blood Pressure in Relation to Cardiovascular Outcome (IDHOCO) investigators
Institutions: Tohoku University, KU Leuven, Ljubljana University Medical Centre, Turku University Hospital, Finnish Institute for Health and Welfare, Tohoku Medical Megabank Organization, Universidad de la República de Uruguay, Hospital de Clínicas, Hospital Italiano de Buenos Aires, Teikyo University, Inserm, Université Bordeaux Segalen, National and Kapodistrian University of Athens, Sotiria General Hospital, Maastricht University
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $6,460
Funders: National Institute for Health and Care Research, European Commission, Työsuojelurahasto, Ministry of Health, Labour and Welfare, Daiwa Securities Health Foundation, Suomen Hammaslääkäriliitto, Vlaamse regering, Japan Society for the Promotion of Science, Barts and The London School of Medicine and Dentistry, FP7 Ideas: European Research Council
Awards: G1440437423, G3341049389, European Network for Genetic-Epidemiological Studies: building a method to dissect complex genetic traits, using essential hypertension as a disease model, G4497842153, EPidemiological Left ventriclar Outcomes Research in Europe, Markers for Sub-Clinical Cardiovascular Risk Assessemnt, G619130249, Population studies regarding genetic background on progression of hypertension and antihypertensive drug effect based on self-measured home blood pressure, Heart OMics in AGEing, G924034392
OpenAlex ID: W2008818755
